Evidence map›Paper›PMID 35721216›Full record

ArticleFrontiers in pharmacology2022

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis

Qi He, Junzheng Yang, Delong Chen, Yejia Li, Dawei Gong, Hui Ge, Zihao Wang, Haibin Wang, Peng Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Leaf Extract ofNutrients · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Qi HeFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Junzheng YangFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Delong ChenDepartment of Orthopaedic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands.
Yejia LiDepartment of Orthopedics, Shunde Hospital, Guangzhou University of Chinese Medicine, Foshan, China.
Dawei GongFirst School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Hui GeDepartment of Orthopedics, Guangzhou Hospital of Integrated Chinese and Western Medicine, Guangzhou, China.
Zihao WangQueen's University Belfast, Belfast, United Kingdom.
Haibin WangDepartment of Orthopaedics, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Peng ChenDepartment of Orthopaedics, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CNErasmus MC · NLIntegrated Chinese Medicine (China) · CNQueen's University Belfast · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is a major health problem in the elderly. Almost every bone can fracture due to the increased bone fragility in osteoporosis, posing a major challenge to public health. 12-Deoxyphorbol-13-hexadecanoate (DHD), one of the main bioactive components of

Indexed as

12-deoxyphorbol-13-hexadecanoateBone lossMAPK signaling pathwayNFATc1ROS

Identifiers

PMID35721216
PMCPMC9204068
OpenAlexW4281901366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.